Regenerative medicine is an emerging field of research that is pioneering ways to regrow, repair, or replace human cells, tissues, and organs that have lost function due to age, disease, damage, or congenital effects. Researchers can either stimulate previously irreparable tissues and organs to heal themselves or grow them in the laboratory and safely implant them into the body when it cannot heal itself.
“These new technologies, most of which are in the early stages of development, hold significant promise to treat and cure diseases, improve the quality of life of patients and put an end to the donor organ shortage. As the world population continues to age rapidly, and the prevalence of diseases rises, the need for safe and effective regenerative medicine products will continue to increase,” said Joe Panetta, president and CEO of Biocom.
Biocom’s Regenerative Medicine Fly-In brought 10 participants from seven companies, including researchers, regulatory experts, and business executives to Washington to meet with officials at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), as well as U.S. Representatives Susan Davis, Scott Peters, Lou Correa, and Judy Chu. Participants had the unique opportunity to discuss new advances in regenerative medicine and the successes and challenges they face.
“Biocom’s fly-in gave us the rare opportunity to connect directly with the high-level officials at the NIH, FDA, and Congress who oversee the research and regulation of cell and gene therapies and tissue products. From receiving clarity on the new regenerative medicine advanced therapy (RMAT) designation to discussing grant funding, we got a much-needed insider’s look into how the regulatory and legislative process affects the development of regenerative medicines. It was also really beneficial to develop relationships with fellow innovators and learn about their research,” said John Chi, CEO of Synova Life Sciences.
Biocom’s fly-in tops almost a year of work within the organization to advance California’s regenerative medicine space. Biocom created and led a coalition of research institutes and companies to analyze the current regenerative landscape, identify challenges and provide recommendations to the FDA. Last month, Biocom submitted several comments to the drug agency providing insight into what needs to be done to support and advance regenerative medicine research in California and across the country.
“This is just the beginning; California is just getting started,” added Panetta.
(Source: Biocom)